Key Highlights

  • Veracyte, Inc. (NASDAQ:VCYT) dropped 54.9% to USD 23.69 after cutting its 2026 testing Revenue outlook, despite third quarter revenue climbing 15% to USD 151.8 million.
  • Akebia Therapeutics (NASDAQ:AKBA) lost 33.91% to USD 0.4591 as third quarter revenue slipped to USD 36.9 million from USD 58.8 million, with Auryxia sales contracting.
  • Adagio Medical Holdings (NASDAQ:ADGM) sank 29.93% one day after disclosing a 1-for-30 reverse split effective November 6, 2026, with convertible notes and a strategic review also in play.
  • SANUWAVE lost 50.44% on light Volume with guidance pulled since August, while Ping An Biomedical Co., Ltd. (NASDAQ:PASW) dropped 41.98% following a USD 2.3 million Patent transaction.

Veracyte, Inc. (NASDAQ:VCYT): Solid Profit, Trimmed Testing Forecast

The largest dollar-value drop in healthcare belongs to Veracyte, Inc. (NASDAQ:VCYT), which changed hands at USD 23.69, down 54.9% in trading on November 5, 2026, according to published market data. Its November 4, 2026 results showed revenue up 15% to USD 151.8 million and GAAP Net Income of USD 31.5 million. The problem lay in the forward view: 2026 testing revenue guidance now sits between USD 571 million and USD 573 million, versus the earlier USD 576 million to USD 582 million, while the adjusted EBITDA Margin outlook above 26% held steady. Leadership pointed to Decipher Prostate volume coming in under expectations. Growth in genomic diagnostics depends on how many tests doctors order, and payers determine what gets reimbursed, so a shortfall in a leading prostate test raises doubts even when cash generation is robust. Published coverage noted that Leerink Partners lowered its rating on November 5, 2026. The company holds USD 370.5 million in cash and short-term investments and has authorized Buybacks of up to USD 100 million. A decline of this size is unusual, and quoted prices can shift before the session ends.

Akebia Therapeutics (NASDAQ:AKBA): Auryxia Declines Quicker Than Vafseo Expands

At Akebia Therapeutics (NASDAQ:AKBA), the 33.91% decline to USD 0.4591 came after third quarter results released on November 5, 2026. Total revenue reached USD 36.9 million compared with USD 58.8 million, as Auryxia net product revenue fell to USD 20.0 million from USD 42.5 million. Vafseo edged up to USD 14.8 million from USD 14.3 million, a result management linked to the biggest customer trimming its inventory, though the number of patients on therapy hit about 11,500, roughly 140% higher than a year earlier. The company moved to a net loss of USD 14.4 million from net income of USD 0.5 million. Cash stood at USD 159.3 million, which management said should support the current plan for at least two years. Older medicines lose sales as generic versions and rivals take share, so the central question is whether the newer drug can grow faster than the decline. The company intends to refinance its senior secured term Loan but has not said how much. A share price under USD 1 can also draw scrutiny under the Nasdaq minimum bid rule, and moves in low-priced quotes can reverse quickly.

Adagio Medical Holdings (NASDAQ:ADGM): A Reverse Split Amid Tight Funding

The 29.93% slide at Adagio Medical Holdings (NASDAQ:ADGM), to about USD 0.0604, came one day after the company unveiled a 1-for-30 reverse split, approved by its board and stockholders on October 23, 2026 and set to take effect November 6, 2026. Each 30 shares will merge into one, with fractional holdings settled in cash. A reverse split leaves company value untouched. The bigger concern is financing. In a September 23, 2026 filing, the firm said its 13% senior secured convertible notes would convert at the lower of the prevailing price or 85% of the lowest five-day volume-weighted average price, meaning holders receive more shares as the stock declines. Preliminary cash and marketable securities came to about USD 7.7 million at June 30, 2026, and the company eliminated 25 of its 43 full-time positions while its board weighs strategic options. On the clinical side, a premarket approval application for the vCLAS cryoablation system reached the FDA on May 21, 2026, supported by FULCRUM-VT data from 209 patients. With a Market Value near USD 1.66 million, quoted prices can swing sharply in either direction.

SANUWAVE Health, Inc. (NASDAQ:SNWV): A Medicare Decision Looms Over a Thinly Traded Stock

At SANUWAVE Health, Inc. (NASDAQ:SNWV), the 50.44% fall to USD 2.84 lacked an identifiable same-day catalyst, so the most recent verified update provides context. On August 6, 2026 the company posted second quarter revenue of USD 9.7 million, a 3% decline, with gross margin at 76.2% versus 78.1%. It withdrew 2026 guidance pending the final Centers for Medicare and Medicaid Services rule, expected in the fourth quarter. Management attributed the weakness to a sharp fall in system sales even as applicator sales hit a record, and highlighted Medicare reimbursement changes and a 2027 proposed rule covering code 97610. Reimbursement rules determine how much clinics will pay for wound care equipment, so a payment shift can cut Demand quickly. Third quarter results appear on published calendars for around November 6, 2026, a date the company has not confirmed in this review. Volume was only about 214,000 shares and market value is roughly USD 40 million to USD 50 million, so a few trades can move the price and bid-ask spreads can widen. The drop should not be treated as a trend.

Shifting From Apparel Supply Chains Toward Oncology Patents

The 41.98% decline at Ping An Biomedical Co., Ltd. (NASDAQ:PASW), to USD 1.70 on roughly 67,000 shares, followed a November 4, 2026 announcement of a binding purchase agreement for three tumor cell patents from Future Biotechnology Group Co., Limited for USD 2.3 million, which came after a non-binding letter of intent dated October 22, 2026. The patents address oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. The announcement left the payment form unspecified, with closing and registration still pending. The firm's Chinese Subsidiary handles garment supply chain work, so entering biomedicine is a significant change, and patents produce no revenue until they are developed, licensed or commercialized. One Shareholder controls about 91.56% of voting power, a shelf registration allows up to USD 300 million of securities, and a 1-for-40 reverse split announced October 21, 2026 appears only in published coverage. With a market value near USD 5 million, quoted prices can reverse, and the drop should not be read as a trend.

Where Things Stand

The shared theme is that healthcare decliners span a profitable diagnostics company resetting growth expectations to nano-caps squeezed by financing, so the weight of evidence suggests the causes matter more than the size of the decline. Veracyte, Inc. (NASDAQ:VCYT) and Akebia reported actual operating developments. Adagio Medical Holdings (NASDAQ:ADGM), SANUWAVE and Ping An Biomedical are small, thinly traded names where dilution, regulation and Business pivots weigh heavily. Quoted declines may reverse, and nothing here signals a rebound or further slide. Upcoming markers include Veracyte fourth quarter prostate volumes, the Akebia refinancing, the November 11, 2026 Adagio results and the CMS rule affecting SANUWAVE Health, Inc. (NASDAQ:SNWV).